E-17<i>α</i>-(2-[<sup>125</sup>I]IODOVINYL)-19-NORTESTOSTERONE: THE SYNTHESIS OF A GAMMA-EMITTING LIGAND FOR THE PROGESTERONE RECEPTOR.

Hochberg, Richard B.; Hoyte, Robert M.; Rosner, William

doi:10.1210/endo-117-6-2550

Cited by 34 publications

(13 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During the 1980's Hochberg, et al described the preparation of the 17α-iodovinyl testosterone (ethisterone) and 19-nortestosterone (norethisterone) analogs in their radiolabeled form using the halodestannylation methodology [18,19]. The Schering group also explored these as potential results essentially confirmed previous findings regarding the inadequacy of the ligands.…”

Section: B Progesterone Receptor Ligandsmentioning

confidence: 77%

Synthesis of Auger Electron-Emitting Radiopharmaceuticals

Hanson

2000

CPD

View full text Add to dashboard Cite

Targeted radiotherapy using Auger electron-emitting pharmaceuticals offers both advantages and challenges compared to alternative alpha - or beta -emitting agents. The low energy Auger electrons deposit their energy within the target cell thereby minimizing collateral damage. To achieve this effect, however, the radiopharmaceutical must incorporate the appropriate radionuclide, be efficiently synthesized, and once administered, be distributed selectively to its biological target. This review covers the synthesis of agents which have prepared over the past decade either as Auger electron-emitting radiopharmaceuticals or which have the potential as such. While not an exhaustive review, the major classes of agents, such as hormone receptor ligands, nucleoside analogs and intercalating agents are described.

show abstract

Section: B Progesterone Receptor Ligandsmentioning

confidence: 77%

Synthesis of Auger Electron-Emitting Radiopharmaceuticals

Hanson

2000

CPD

View full text Add to dashboard Cite

show abstract

“…Early reports of PET imaging agents for the progesterone receptor (PgR), published in the 1970s and 1980s, described the synthesis of 21-[ 18 F]fluoroprogesterone, a direct analog of the endogenous progestational hormone, progesterone, as well as some analogs of this compound and ones substituted at different sites; however, no PgR binding was reported, and biodistribution and metabolism studies were limited and generally disappointing [ 60 , 61 , 62 ]. High-affinity radioiodinated ligands for PgR, reported at the same time, appeared more promising, especially (Z)-17β-hydroxy-17α-(2-iodovinyl)-4-estren-3-one and the bromo analog [ 63 , 64 , 65 , 66 , 67 ], and these showed some evidence of PgR-specific uptake in the uterus of estrogen-primed immature rats [ 24 , 68 ].…”

Section: Ffnp a Pet Imaging Agent For Progesterone Receptors In Bmentioning

confidence: 99%

PET Imaging Agents (FES, FFNP, and FDHT) for Estrogen, Androgen, and Progesterone Receptors to Improve Management of Breast and Prostate Cancers by Functional Imaging

Katzenellenbogen

2020

Cancers

View full text Add to dashboard Cite

Many breast and prostate cancers are driven by the action of steroid hormones on their cognate receptors in primary tumors and in metastases, and endocrine therapies that inhibit hormone production or block the action of these receptors provide clinical benefit to many but not all of these cancer patients. Because it is difficult to predict which individuals will be helped by endocrine therapies and which will not, positron emission tomography (PET) imaging of estrogen receptor (ER) and progesterone receptor (PgR) in breast cancer, and androgen receptor (AR) in prostate cancer can provide useful, often functional, information on the likelihood of endocrine therapy response in individual patients. This review covers our development of three PET imaging agents, 16α-[18F]fluoroestradiol (FES) for ER, 21-[18F]fluoro-furanyl-nor-progesterone (FFNP) for PgR, and 16β-[18F]fluoro-5α-dihydrotestosterone (FDHT) for AR, and the evolution of their clinical use. For these agents, the pathway from concept through development tracks with an emerging understanding of critical performance criteria that is needed for successful PET imaging of these low-abundance receptor targets. Progress in the ongoing evaluation of what they can add to the clinical management of breast and prostate cancers reflects our increased understanding of these diseases and of optimal strategies for predicting the success of clinical endocrine therapies.

show abstract

“…125 I-VNT is a specific, high-affinity ligand for the progestin receptor (Hochberg et al 1985) with a specific activity more than four times greater than that of [ 3 H]R5020. As shown in Fig.…”

Section: Identification Of the Progestin Receptor In Sucrose Density mentioning

confidence: 99%

Characterization of the progestin receptors in the human TE85 and murine MC3T3-E1 osteoblast-like cell lines

Gunnet¹,

Granger²,

Cryan³

et al. 1999

Journal of Endocrinology

View full text Add to dashboard Cite

Progestins are believed to exert positive effects on bone density through receptors located in osteoblasts. In the present studies, the binding characteristics and regulation of the progestin receptors in two osteoblast-like cell lines were compared with those in human breast lines. Human TE85 and murine MC3T3-E1 osteoblast-like cells contain a single, high-affinity progestin binding site whose affinity and concentration are lower than in human breast cells. The osteoblastic progestin binding sites showed the expected steroid specificity and associated with the cell nuclei when occupied by ligand. The progestin receptors in osteoblastic cells also had sedimentation coefficients similar to those receptors in breast cells. The regulation of the progestin receptor in the osteoblast-like cells was explored by treating them with estradiol. In contrast to the large, rapid change seen in the breast cells, the progestin receptor levels in the MC3T3-E1 cells showed only a small, delayed up-regulation with estradiol treatment. The progestin receptor number in the TE85 cells was unaffected by estradiol. Down-regulation of the progestin receptors was explored by treating the cells with the progestin, norethindrone (NET). NET administration produced a rapid drop in progestin binding sites in the breast cells and a smaller, more gradual decline in MC3T3-E1 progestin binding. While the maximal decrease in receptor number occurred within 24 h in the breast cells, the receptor number was still continuing to fall after 72 h in the MC3T3-E1 cells. The data presented here demonstrate that both human and murine osteoblastlike cells contain a functional progestin receptor whose binding characteristics and regulation are similar, but not identical, to those receptors in other progestin target tissues such as the breast.

show abstract

E-17α-(2-[¹²⁵I]IODOVINYL)-19-NORTESTOSTERONE: THE SYNTHESIS OF A GAMMA-EMITTING LIGAND FOR THE PROGESTERONE RECEPTOR.

Cited by 34 publications

References 7 publications

Synthesis of Auger Electron-Emitting Radiopharmaceuticals

Synthesis of Auger Electron-Emitting Radiopharmaceuticals

PET Imaging Agents (FES, FFNP, and FDHT) for Estrogen, Androgen, and Progesterone Receptors to Improve Management of Breast and Prostate Cancers by Functional Imaging

Characterization of the progestin receptors in the human TE85 and murine MC3T3-E1 osteoblast-like cell lines

Contact Info

Product

Resources

About

E-17α-(2-[125I]IODOVINYL)-19-NORTESTOSTERONE: THE SYNTHESIS OF A GAMMA-EMITTING LIGAND FOR THE PROGESTERONE RECEPTOR.

Cited by 34 publications

References 7 publications

Synthesis of Auger Electron-Emitting Radiopharmaceuticals

Synthesis of Auger Electron-Emitting Radiopharmaceuticals

PET Imaging Agents (FES, FFNP, and FDHT) for Estrogen, Androgen, and Progesterone Receptors to Improve Management of Breast and Prostate Cancers by Functional Imaging

Characterization of the progestin receptors in the human TE85 and murine MC3T3-E1 osteoblast-like cell lines

Contact Info

Product

Resources

About

E-17α-(2-[¹²⁵I]IODOVINYL)-19-NORTESTOSTERONE: THE SYNTHESIS OF A GAMMA-EMITTING LIGAND FOR THE PROGESTERONE RECEPTOR.